To assess the prognostic utility of the clinical criteria of the World Health Organization's (WHO) proposed staging system for HIV disease and infection in a cohort of intravenous drug users (IVDU) from the ALIVE study.
All study subjects known to be HIV-seropositive were included in this analysis.
Subjects were classified as WHO clinical stage 1,2, or 3 at their initial seropositive evaluation.
Product-limit estimates and Cox proportional hazard models were used to compare time of progression to AIDS (stage 4) for the first three clinical stages.
Of the original cohort of 2921 IVDU in the ALIVE study, 694 were known to be HIV-positive by january 1992.
At the time of their index visit, 49% of the cohort were WHO clinical stage 1,10% stage 2 and 41% were stage 3.
Mots-clés Pascal : SIDA, Virose, Infection, OMS, Evolution, Toxicomanie, Symptomatologie, Stade clinique, Classification par stade, Prédiction, Voie intraveineuse, Homme, Immunopathologie, Immunodéficit
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, WHO, Evolution, Drug addiction, Symptomatology, Clinical stage, Staging, Prediction, Intravenous administration, Human, Immunopathology, Immune deficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0645316
Code Inist : 002B06D01. Création : 09/06/1995.